과식증 시장 : 치료 유형별, 치료 환경별, 유통 채널별, 최종 사용자별 - 시장 예측(2026-2032년)

The Binge Eating Disorder Market was valued at USD 623.43 million in 2025 and is projected to grow to USD 664.80 million in 2026, with a CAGR of 6.22%, reaching USD 951.57 million by 2032.

Comprehensive introduction outlining the clinical, social, and economic dimensions of binge eating disorder and the imperative for integrated care approaches

Binge eating disorder (BED) is a clinically significant eating disorder characterized by recurrent episodes of consuming large amounts of food accompanied by a perceived loss of control. Beyond diagnostic criteria, the condition carries multifaceted clinical, psychological, and social consequences that affect individuals across age groups and care settings. Individuals living with BED often experience comorbid mood and anxiety disorders, metabolic complications, and functional impairment that together require coordinated, multidisciplinary approaches to care.

Recent shifts in care delivery and technology integration have increased awareness among clinicians and payers, yet gaps remain in timely diagnosis, access to evidence-based therapies, and continuity of care after acute intervention. In addition, stigma and underreporting contribute to delayed treatment seeking, particularly among underserved populations. Consequently, clinical leaders and health system administrators are focused on closing care gaps through diagnostic screening in primary care, integration of behavioral health into medical settings, and expanded training on evidence-based psychotherapies.

Given these dynamics, a strategic introduction to the landscape centers on the need for integrated care pathways that combine behavioral interventions, pharmacologic options where clinically appropriate, and digital therapeutics to extend reach. This introduction frames the priorities that follow: optimizing patient identification, aligning care modalities across settings, and ensuring that commercial and policy decisions support durable, equitable access to effective treatment.

Transformative shifts reshaping clinical pathways, digital adoption, and patient engagement in binge eating disorder treatment ecosystems across care continuums

The treatment landscape for binge eating disorder is undergoing transformative shifts driven by technology, clinical innovation, and evolving payer expectations. Digital therapeutics and telehealth platforms have accelerated patient access to evidence-based psychotherapies and self-management tools, enabling stepped-care approaches that begin in primary care and escalate to specialist intervention when needed. Concurrently, renewed interest in pharmacologic agents and adjunctive treatments has prompted a re-examination of combined-modality strategies where medication is used to support engagement in psychotherapy and reduce symptom severity.

Regulatory frameworks and reimbursement models are responding to these changes, with value-based contracting and outcomes-based reimbursement gaining traction in pockets where measurable clinical outcomes can be demonstrated. These dynamics incentivize developers to prioritize real-world evidence generation and validated outcome measures. At the same time, partnerships between digital health innovators, specialty treatment centers, and payers are becoming more common, reflecting a recognition that no single stakeholder can address access, quality, and affordability alone.

As a result, stakeholders must adapt to an ecosystem where patient engagement platforms, clinical decision support tools, and multidisciplinary care teams intersect. Investment in interoperability, clinician training on digital modalities, and robust data governance are necessary to convert technological promise into improved clinical outcomes. Looking forward, integration of behavioral analytics and precision approaches to treatment selection will further reshape care pathways and help personalize interventions for better long-term recovery.

Assessment of cumulative impacts from United States tariff changes in twenty twenty five on therapeutic supply chains and cross-border clinical collaborations

Policy actions affecting tariffs can have a cumulative impact on the broader healthcare ecosystem and specifically on the supply chains that underpin therapeutics, devices, and digital platforms used in binge eating disorder care. Increases in duties on imported pharmaceuticals or medical devices may raise costs for providers and payers, prompting supply chain managers to adjust sourcing strategies, build larger inventories, or accelerate relocation of manufacturing closer to end markets. These supply-side responses, in turn, influence procurement cycles and contract negotiations across hospitals, specialty centers, and distribution partners.

For digital health providers and platform vendors, indirect impacts can also emerge when hardware components, sensors, or ancillary devices are subject to tariff changes. Higher input costs can necessitate price adjustments or altered product roadmaps, while longer lead times for components can slow device-based pilots or rollouts. Clinical trial logistics and international collaboration on research may face friction if cross-border exchanges of equipment or study materials become more costly or administratively burdensome.

Strategic responses to tariff-driven disruption tend to center on diversification and resilience. Organizations are increasingly pursuing nearshoring, dual-sourcing, and advanced inventory management to reduce exposure to single-country policy shocks. They are also engaging earlier with supply chain and procurement teams when designing clinical programs to account for potential cost and timing variability. Moreover, meaningful contingency planning and transparent communication with payers and provider partners enable smoother transitions and protect patient continuity of care during periods of regulatory and trade uncertainty.

Segmentation insights on how treatment type, distribution channel, end-user demographics, and treatment setting influence clinical pathways and care delivery

Understanding how care is delivered for binge eating disorder requires a granular look at segmentation across treatment modality, distribution, end users, and care setting. Based on Treatment Type, the market is studied across Digital Therapeutics, Pharmacotherapy, and Psychotherapy, with Digital Therapeutics further studied across Mobile App and Web Based delivery models, Pharmacotherapy further studied across Antidepressants, Antiepileptics, and Stimulants, and Psychotherapy further studied across Cognitive Behavioral Therapy, Dialectical Behavior Therapy, and Interpersonal Psychotherapy. These subsegments each present unique regulatory, clinical validation, and commercialization requirements: digital therapeutics must demonstrate engagement and clinical effect across digital endpoints, pharmacotherapies must navigate safety and labeling pathways, and psychotherapeutic modalities require workforce training and fidelity monitoring to scale effectively.

In parallel, distribution channels frame access points for care. Based on Distribution Channel, the market is studied across Home Healthcare, Hospitals And Clinics, Online Platforms, and Specialty Treatment Centers, each of which imposes distinct operational needs around clinician workflows, reimbursement codes, and integration with electronic health records. Home healthcare and online platforms expand reach into patient daily environments but require robust remote monitoring and privacy safeguards. Hospitals and clinics provide diagnostic capacity and acute management, while specialty treatment centers concentrate expertise for complex or refractory cases.

Patient populations shape demand and design of services. Based on End User, the market is studied across Adolescents, Adults, and Elderly populations, and differentiation by age group influences clinical features, comorbidity profiles, and engagement preferences. Adolescents may access school-based screening and family-centered interventions, adults often require integrated management for metabolic comorbidities, and elderly patients need attention to polypharmacy and age-specific psychosocial supports. Finally, the setting in which care is delivered matters. Based on Treatment Setting, the market is studied across Inpatient and Outpatient environments, with inpatient care reserved for high-acuity stabilization while outpatient services form the backbone of long-term recovery and relapse prevention. Recognizing these segmentation layers enables stakeholders to align product design, reimbursement strategies, and clinical pathways to meet the needs of distinct user cohorts and care settings.

Regional insights comparing prevalence, care infrastructure, reimbursement, and innovation adoption that shape treatment access and service delivery

Regional dynamics exert strong influence on how binge eating disorder is identified, treated, and reimbursed, and they therefore shape strategic priorities for clinical programs and commercial planning. In the Americas, higher clinician awareness and expanding telehealth infrastructure support broader rollout of integrated care models, but regional heterogeneity in public and private payer policies means that reimbursement and access pathways vary significantly between jurisdictions. This drives a need for localized engagement with payers and health systems to demonstrate value through outcomes and cost-offset analyses.

In Europe, Middle East & Africa, regulatory frameworks and cultural context differ across countries, which affects adoption patterns. Some European markets have established behavioral health integration and national guidelines that facilitate standardized care pathways, while other jurisdictions within the Middle East and Africa are at earlier stages of diagnostic capacity and workforce development. These differences necessitate tailored approaches that consider local clinical training, stigma reduction, and infrastructure investments to expand access.

The Asia-Pacific region presents diverse opportunities and challenges due to variation in digital adoption, population demographics, and regulatory regimes. High mobile penetration in many Asia-Pacific markets supports rapid diffusion of mobile app-based interventions, yet language, cultural norms around eating behavior, and evolving reimbursement policies require careful localization of clinical content and engagement models. Across all regions, stakeholders benefit from region-specific evidence, partnerships with local clinical leaders, and capacity-building initiatives that reflect each region's unique epidemiology and healthcare delivery architecture.

Company-level insights on strategic positioning, collaborations, research priorities, and differentiation among treatment and digital therapy providers

Company strategies in the binge eating disorder landscape are defined by a mix of clinical innovation, strategic partnerships, and targeted commercialization models. Leading clinical developers and digital therapy providers are investing in rigorous outcome measurement, demonstrating efficacy through randomized studies and real-world evidence to support payer conversations. At the same time, alliances between technology providers and established behavioral health networks are enabling pilots that integrate digital tools into existing care pathways, reducing friction for clinician adoption and patient onboarding.

Pharmaceutical stakeholders pursuing pharmacologic options are focusing on differentiation through mechanism of action, tolerability, and evidence of sustained symptom reduction, while also considering the role of adjunctive use with psychotherapy. Specialty treatment centers and hospital systems are exploring value-based contracting arrangements tied to measurable recovery metrics, which encourages providers to report outcomes and iterate on care delivery models. New entrants are leveraging data science to refine patient segmentation and identify which interventions are most likely to succeed for particular patient profiles, creating opportunities for personalized care solutions.

Across the sector, the most successful organizations combine clinical credibility with distribution acumen, prioritizing interoperability, clinician engagement, and payer alignment. They also maintain flexible commercialization roadmaps that allow rapid local adaptation, accelerated partnership models, and investment in training programs to ensure fidelity to evidence-based interventions.

Actionable recommendations for leaders to accelerate adoption, strengthen care pathways, and align strategies with changing clinical and regulatory landscapes

Industry leaders should pursue a set of actionable initiatives that accelerate access to evidence-based care while protecting commercial viability. First, prioritize integrated care models that combine psychotherapeutic interventions with pharmacologic and digital options, and invest in longitudinal outcome measurement to demonstrate clinical and economic value. Second, develop interoperability and clinician-friendly workflows that make digital therapeutics a seamless component of routine care, thereby lowering adoption barriers and improving adherence.

Third, strengthen payer engagement by co-designing outcome frameworks and piloting value-based reimbursement models that reward sustained recovery rather than episodic service delivery. Fourth, insulate supply chains against policy shocks and trade disruptions through diversification, nearshoring where feasible, and transparent procurement strategies that account for potential tariff impacts. Fifth, invest in workforce capacity through clinician training programs focused on evidence-based psychotherapies and on integrating digital tools into therapeutic practice.

Finally, adopt an evidence-first commercialization strategy that sequences clinical validation, payer pilots, and provider partnerships to build credibility and scale. By aligning product development with clear clinical endpoints and payer needs, organizations can reduce commercial risk and accelerate uptake while maintaining ethical standards and patient-centered design principles.

Transparent methodology outlining data sources, analytical frameworks, validation steps, and quality controls to ensure rigorous and reproducible insights

The analysis underpinning this report uses a multi-source, evidence-driven methodology designed to maximize reliability and transparency. Primary inputs include peer-reviewed clinical literature, registry and trial databases, regulatory documents, and qualitative interviews with clinicians, payers, digital health innovators, and supply chain experts. These inputs were triangulated to reconcile differences in study design, patient populations, and outcome measures, and to assess the robustness of clinical effects across settings.

Quantitative findings were supplemented with qualitative insights from subject-matter experts and frontline providers to contextualize adoption barriers and implementation considerations. Data curation and synthesis followed a reproducible protocol: source provenance was recorded, analytical assumptions were documented, and internal replication checks were performed. Validation steps included cross-checking clinical effect estimates against trial registries, reviewing reimbursement pathways with payer consultants, and testing supply chain scenarios with procurement specialists to ensure scenario plausibility.

Limitations are acknowledged: evidence quality varies by intervention type, and some emerging modalities have limited long-term outcome data. To mitigate these constraints, the methodology emphasizes transparency and recommends ongoing evidence generation post-deployment. This approach supports decision-makers who require both rigor and practical guidance when planning clinical programs, commercial launches, or policy engagement.

Conclusive synthesis emphasizing strategic priorities, urgency of integrated care, and a clear pathway forward for stakeholders across clinical and policy domains

The landscape for binge eating disorder is characterized by both opportunity and complexity. Advances in digital therapeutics, renewed pharmacologic inquiry, and evolving care models collectively create avenues to improve access and outcomes, but realizing that potential requires coordinated action across clinical, commercial, and policy stakeholders. Integrated care pathways that bring together psychotherapy, pharmacotherapy, and digital supports are central to delivering sustained benefit and reducing relapse.

At the same time, external forces such as trade policy changes and regional differences in reimbursement and infrastructure introduce practical constraints that demand resilient supply chains, localized engagement strategies, and an evidence-driven approach to payer conversations. Organizations that invest in interoperability, real-world evidence generation, and clinician training will be better positioned to convert scientific advances into meaningful, scalable care.

In summary, the most effective path forward combines clinical rigor with operational resilience and stakeholder collaboration. By aligning investments with clear outcome metrics and by designing services that reflect the lived experience of patients across diverse settings and regions, stakeholders can advance both clinical and commercial goals while expanding equitable access to effective treatment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Binge Eating Disorder Market, by Treatment Type

• 8.1. Digital Therapeutics
  • 8.1.1. Mobile App
  • 8.1.2. Web Based
• 8.2. Pharmacotherapy
  • 8.2.1. Antidepressants
  • 8.2.2. Antiepileptics
  • 8.2.3. Stimulants
• 8.3. Psychotherapy
  • 8.3.1. Cognitive Behavioral Therapy
  • 8.3.2. Dialectical Behavior Therapy
  • 8.3.3. Interpersonal Psychotherapy

9. Binge Eating Disorder Market, by Treatment Setting

• 9.1. Inpatient
• 9.2. Outpatient

10. Binge Eating Disorder Market, by Distribution Channel

• 10.1. Home Healthcare
• 10.2. Hospitals And Clinics
• 10.3. Online Platforms
• 10.4. Specialty Treatment Centers

11. Binge Eating Disorder Market, by End User

• 11.1. Adolescents
• 11.2. Adults
• 11.3. Elderly

12. Binge Eating Disorder Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Binge Eating Disorder Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Binge Eating Disorder Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Binge Eating Disorder Market

16. China Binge Eating Disorder Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Alsana, Inc.
• 17.6. Amneal Pharmaceuticals, Inc.
• 17.7. Apotex Inc. by SK Capital Partners LLP
• 17.8. BALANCE Eating Disorder Treatment Center
• 17.9. Carolina House Eating Disorder Treatment Center
• 17.10. Center for Change
• 17.11. Equip Health, Inc.
• 17.12. Hikma Pharmaceuticals PLC
• 17.13. Jazz Pharmaceuticals plc
• 17.14. Johnson & Johnson Innovative Medicine by Johnson and Johnson
• 17.15. Monte Nido & Affiliates Holdings, LLC
• 17.16. Montecatini Eating Disorder Treatment Center
• 17.17. Novo Nordisk A/S
• 17.18. Pfizer Inc.
• 17.19. Red Oak Recovery
• 17.20. Rhodes Pharmaceuticals L.P. by Purdue Pharma L.P.
• 17.21. SimSon Pharma Limited
• 17.22. Sunovion Pharmaceuticals Inc. by Sumitomo Pharma
• 17.23. Takeda Pharmaceutical Company Limited
• 17.24. TalktoAngel
• 17.25. The London Centre for Eating Disorders and Body Image Ltd.
• 17.26. TheraCryf Plc
• 17.27. Timberline Knolls Residential Treatment Center
• 17.28. Viatris Inc.